Please login to the form below
Biosimilars in 2018: EU doctors’ perceptions of RA drug market
Published in pharmaphorum October 2015 by Laurent Chanroux
Physicians in Europe's Big 5 think current market leaders will continue to lead, with biosimilars making the greatest inroads in the field up to 2018, if clearer guidance on efficacy and safety is provided.
A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they currently treat their patients and what they expect to be doing in 2018. The findings suggest that the market leaders can breathe easy, for the moment at least.
Read the full article here:
www.researchpartnership.com/news/2015/10/article-biosimilars-in-2018-ra-perceptions/
A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they currently treat their patients and what they expect to be doing in 2018. The findings suggest that the market leaders can breathe easy, for the moment at least.
Read the full article here:
www.researchpartnership.com/news/2015/10/article-biosimilars-in-2018-ra-perceptions/
Company Details
Research Partnership
+44 (0)20 8069 5000
Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom
Latest content on this profile
- Announcing a change of leadership at the US Philadelphia office
Research Partnership
- Article: Market access in Brazil
- All eyes on Spinraza
Research Partnership
- China: How to strategise and win in the world's fastest changing healthcare market
Research Partnership
- Infographic: Preparing to launch a new asset and in need of demand assessment research?
- Download our pre-launch checklist
Research Partnership
- Article: Engaging patient advocacy groups
- The key to conducting effective rare disease research
Research Partnership
- Webcast: Harnessing the power of social: How to generate fresh insights for your business using social media listening
Research Partnership
